HDAC8 and neuroblastoma: In 2018, Kolbinger et al. disclosed the structure of TH34 (61, Figure 11), a novel HDAC6/8/10 inhibitor capable of selectively inhibiting the three isoforms in low-micromolar concentrations (HDAC6 IC50 = 4.6 μM; HDAC8 IC50 = 1.9 μM; HDAC10 IC50 = 7.7 μM), as a potential therapeutic agent for the treatment of high-grade neuroblastoma.